Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

PURPOSE: Soft-tissue sarcomas (STS) are a rare, heterogeneous group of mesenchymal tumors. For decades the mainstay of treatment for advanced, unresectable STS has been palliative chemotherapy. High levels of activated MET receptor have been reported in various sarcoma cell lines, together with elev...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Sullivan Coyne, Geraldine, Kummar, Shivaani, Hu, James, Ganjoo, Kristen, Chow, Warren A., Do, Khanh T., Zlott, Jennifer, Bruns, Ashley, Rubinstein, Lawrence, Foster, Jared C., Juwara, Lamin, Meehan, Robert, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Takebe, Naoko, Voth, Andrea Regier, Bottaro, Donald, Costello, Rene, Wright, John J., Doroshow, James H., Chen, Alice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776602/
https://www.ncbi.nlm.nih.gov/pubmed/34716194
http://dx.doi.org/10.1158/1078-0432.CCR-21-2480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776602/
https://www.ncbi.nlm.nih.gov/pubmed/34716194
http://dx.doi.org/10.1158/1078-0432.CCR-21-2480

Ejemplares similares